Physician profile
Geraldo M Sioco
NPI 1255398699
$7,619.08
in general payments reported to CMS, 2019-2025
26 companies · $956 in 2025
The $956 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,605 · 2020: $1,233 · 2021: $936 · 2022: $843 · 2023: $634 · 2024: $412 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Travel and Lodging: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.00 |
| Travel and Lodging | $274.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,775.52 | 2019-2025 | Watchman, Watchman Flx, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $1,053.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $531.51 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $444.39 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $425.65 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $383.15 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.79 | 2019-2025 | Jardiance |
| Amgen INC. | $368.97 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $273.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $234.91 | 2020-2025 | Eliquis, Camzyos |
| Pfizer INC. | $211.95 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $73.17 | 2019-2021 | |
| Scpharmaceuticals INC. | $65.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $60.54 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $51.80 | 2023-2024 | Edarbi, Edarbi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.33 | 2019 | |
| Braemar Manufacturing, LLC | $35.35 | 2019 | |
| Preventice Services, LLC | $35.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.64 | 2019 | |
| Itamar Medical INC | $31.66 | 2022 | |
| Acist Medical Systems, INC. | $24.00 | 2024 | |
| Althera Pharmaceuticals LLC | $18.01 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.40 | 2021 | |
| Lundbeck LLC | $15.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.03 | 2019 | |
| Gilead Sciences, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldo Sioco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.